The beneficial effect of a beta-D-xyloside, iliparcil, in the prevention of postthrombolytic rethrombosis in the rat

Citation
P. Chicaud et al., The beneficial effect of a beta-D-xyloside, iliparcil, in the prevention of postthrombolytic rethrombosis in the rat, HAEMOSTASIS, 28(6), 1998, pp. 313-320
Citations number
23
Categorie Soggetti
Cardiovascular & Hematology Research
Journal title
HAEMOSTASIS
ISSN journal
03010147 → ACNP
Volume
28
Issue
6
Year of publication
1998
Pages
313 - 320
Database
ISI
SICI code
0301-0147(199811/12)28:6<313:TBEOAB>2.0.ZU;2-H
Abstract
The effect of Iliparcil, a new orally active beta-D-xyloside venous antithr ombotic, was studied on the rethrombosis following thrombolytic therapy in rats, using a modified Umetsu model. The drug was administered by oral rout e prior to thrombolytic therapy, which consisted of administering a combina tion of heparin and urokinase (H/U) at 37.5 and 70,000 IU/kg, respectively. Time to reocclusion increased from 3.9 min with saline to 10.5 min followi ng H/U injection. When Iliparcil (30 mg/kg, oral route) was administered 4 h before H/U injection, the time to reocclusion was increased by 250% compa red with H/U alone (p < 0.001). Similarly, dermatan sulfate (DS), administe red intravenously (3 mg/kg) 5 min before thrombus induction, also increased the time to reocclusion (300% compared with H/U alone; p < 0.001). It was also shown that times to reocclusion following Iliparcil or DS treatments w ere still increased even when heparin dosage was decreased. These results s uggest that an antithrombotic product derived from the beta-D-xyloside fami ly could be advantageously used in combination with thrombolytic treatment instead of heparin, which causes complications and side effects.